Literature DB >> 27805296

The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras/ERK and Ras/mTOR pathways.

Masanobu Tsubaki1, Daichiro Fujiwara1,2, Tomoya Takeda1, Toshiki Kino1, Yoshika Tomonari1, Tatsuki Itoh3, Motohiro Imano4, Takao Satou5, Katsuhiko Sakaguchi2, Shozo Nishida1.   

Abstract

Statins induce apoptosis of tumour cells by inhibiting the prenylation of small G-proteins. However, the details of the apoptosis-inducing mechanisms remain poorly understood. The present study showed that the induction of apoptosis by statins in four different human head and neck squamous cell carcinoma (HNSCC) cell lines, HSC-3, HEp-2, Ca9-22, and SAS cells was mediated by increased caspase-3 activity. Statins induced apoptosis by the suppression of geranylgeranyl pyrophosphate biosynthesis. Furthermore, statins decreased the levels of phosphorylated ERK and mTOR by inhibiting the membrane localization of Ras and enhancing Bim expression in HSC-3 and HEp-2 cells. We also found that in all the cell types analyzed, the IC50 values for fluvastatin and simvastatin were highest in HEp-2 cells. In addition, HSC-3, Ca9-22, and SAS cells had higher Ras expression and membrane localization, higher activation of ERK1/2 and mTOR, and lower levels of Bim expression than HEp-2 cells. Our results indicate that statins induce apoptosis by increasing the activation of caspase-3 and by enhancing Bim expression through inhibition of the Ras/ERK and Ras/mTOR pathways. Furthermore, the sensitivity of HNSCC cells to statin treatment was closely related to Ras expression and prenylation levels, indicating that statins may act more effectively against tumours with high Ras expression and Ras-variability. Therefore, our findings support the use of statins as potential anticancer agents.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Bim; Ras; extracellular signal regulated-protein kinase ½; mammalian target of rapamycin; statins

Mesh:

Substances:

Year:  2017        PMID: 27805296     DOI: 10.1111/1440-1681.12690

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

1.  Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.

Authors:  Hannah M Jones; Ziwei Fang; Wenchuan Sun; Leslie H Clark; Jessica E Stine; Arthur-Quan Tran; Stephanie A Sullivan; Timothy P Gilliam; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms.

Authors:  Ali Fatehi Hassanabad
Journal:  Transl Lung Cancer Res       Date:  2019-10

3.  Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer.

Authors:  Mohammad Azhar Kamal; Imran Siddiqui; Cristina Belgiovine; Marialuisa Barbagallo; Valentina Paleari; Daniela Pistillo; Chiara Chiabrando; Silvia Schiarea; Barbara Bottazzi; Roberto Leone; Roberta Avigni; Roberta Migliore; Paola Spaggiari; Francesca Gavazzi; Giovanni Capretti; Federica Marchesi; Alberto Mantovani; Alessandro Zerbi; Paola Allavena
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

4.  Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Masaki Noguchi; Minami Jinushi; Shiori Seki; Yuusuke Morii; Kazunori Shimomura; Motohiro Imano; Takao Satou; Shozo Nishida
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

5.  The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study.

Authors:  Daiji Nagayama; Atsuhito Saiki; Kohji Shirai
Journal:  Vasc Health Risk Manag       Date:  2021-04-28

6.  Effect of Statins on Survival Following Stroke in Patients With Cancer.

Authors:  Ye Sel Kim; Moo-Seok Park; Jun-Hwa Lee; Jong-Won Chung; Mi Ji Lee; Chi Kyung Kim; Jin-Man Jung; Kyungmi Oh; Oh Young Bang; Geong-Moon Kim; Ji-Mi Choi; Juneyoung Lee; Chin Sang Chung; Kwang Ho Lee; Woo-Keun Seo
Journal:  Front Neurol       Date:  2018-04-24       Impact factor: 4.003

7.  Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.

Authors:  Takuro Ishikawa; Yoshinao Z Hosaka; Colin Beckwitt; Alan Wells; Zoltán N Oltvai; Katsuhiko Warita
Journal:  Oncotarget       Date:  2018-06-29

Review 8.  Pleiotropic use of Statins as non-lipid-lowering drugs.

Authors:  Qijia Zhang; Jianlong Dong; Ze Yu
Journal:  Int J Biol Sci       Date:  2020-08-13       Impact factor: 6.580

Review 9.  Crosstalk between Statins and Cancer Prevention and Therapy: An Update.

Authors:  Beniamin Oskar Grabarek; Dariusz Boroń; Emilia Morawiec; Piotr Michalski; Veronica Palazzo-Michalska; Łukasz Pach; Barbara Dziuk; Magdalena Świder; Nikola Zmarzły
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.